鼻副鼻腔悪性黒色腫のBCG療法 : 特にBCG腸溶カプセル経口投与について

概要

論文の詳細を見る
Seven patients with malignant melanoma in the nasal cavity and paranasal sinuses were treated with BCG immunotherapy in authors clinic during 3 years from September, 1976 to November, 1979.In case 1 (stage IV) and case 2 (stage IV), BCG was injected into the tumor tissue with combination of 60Co irradiation. The treatment was ineffective for case 1, who died after 4 months. It appeared to be effective for case 2, who eventually died after 10 months.Other cases were treated with BCG enterosoluble capsule (per orally 80 mg/w) for 5 to 13 months. In case 3 (stage II), and case 6 (stage I), good results were obtained for the prevention of postoperative recurrences. In case 5 (stage IV), a diminution of a metastatic tumor in the lung was observed after administration of BCG capsule. In case 4 (stage II) and case 5, a diminution of metastatic tumors in the skin, lung and brain was observed after administration of BCG capsule combined with DTIC injection. In case 7 (stage IV), a slight growing of a metastatic tumor in the lung was observed during administration of BCG capsule.BCG enterosoluble capsule may be used for a long time, for the enhancement of the effect of BCG immunotherapy, since non or minimal side effect has been noted.